Healthcare
Remedent, Inc.(REMI)
Live Price
Offline$0.0007
+0.00% today
1Y Change
-93.00%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +14.2%
- EPS Growth
- +81.7%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Remedent, Inc. (REMI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 93.0% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +14.2%, EPS growth of +81.7%, a dividend yield of 0.0%. What stands out right now is revenue +14.2%, EPS +81.7%, free cash flow -145.9% with operating margin -12.5% and ROIC -5.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines REMI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+14.2% vs +7.6% peer median
Operating Margin
Below sector median
-12.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Dec 31, 2023, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +14.2% and EPS at +81.7%, with operating margin around -12.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2023 Dec 31, 2023 | โ | +0.0% | +0.0% | -10.2% |
2021 Feb 16, 2021 | โ | +0.0% | +0.0% | -10.2% |
2020 Nov 16, 2020 | โ | +0.0% | +0.0% | -10.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REMI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
REMI Max Drawdown
-98.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for REMI and SPY.
Company Overview
Remedent, Inc.
Other OTC
Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. It also provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth. In addition, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice, which enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. Further, it provides dental implant solutions and treatment concepts. The company sells its products to dental professionals in approximately 30 countries, including Asia, Europe, the Middle East, Canada, and the United States through its internal sales force and third party distributors. The company was founded in 1986 and is headquartered in Ghent, Belgium.
- Leadership
- Guy De Vreese
- IPO Date
- Mar 1, 2006
- Employees
- 3
- Street Address
- Zuiderlaan 1-3
- Mailing
- Gent, 9000
- Region
- Gent, BE
- Reporting Currency
- USD
- Investor Line
- 32 9 241 58 80
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +14.2%
- EPS
- +81.7%
- Free Cash Flow
- -145.9%
Profitability
- Gross Margin
- 61.2%
- Operating Margin
- -12.5%
- Net Margin
- -27.8%
- ROE
- -11.3%
- ROIC
- -5.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 0.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.